For SKYE holders, the transaction represents extreme dilution with only 5.38% pro-forma ownership. Monitor shareholder vote and potential for competing bids. The CVR provides some contingent upside but is highly uncertain. The combined company's cash runway into 2029 and RXC008 Phase 2 catalyst in H2 2028 are the key value drivers for the new entity.
Price Chart
Executive Summary
Skye Bioscience announces a reverse merger with private UK biotech Redx Pharma, forming Fibrx Therapeutics focused on fibrosis. Pre-Transaction Skye shareholders will own only ~5.38% of the combined company, representing extreme dilution. The combined entity receives $125M in committed financing to fund RXC008 through Phase 2 topline data expected H2 2028.
Key Facts
- Skye to acquire Redx Pharma via scheme of arrangement; combined company to be named Fibrx Therapeutics
- Pre-Transaction Skye equity holders to own approximately 5.38% of the combined company
- Pre-Transaction Redx holders to own ~46.17%; Financing investors to own ~48.45%
- Aggregate financings of approximately $125 million committed (PIPE $68M, Series A $36M, Equity Line Facility up to $22M)
- Lead asset RXC008 (GI-restricted pan-ROCK inhibitor) for fibrostenotic Crohn's disease, Phase 2 ready with topline data expected H2 2028
- Skye shareholders to receive CVRs entitling them to 90% of net proceeds from monetization of nimacimab within 12 months post-close
- Expected transaction close in Q4 2026, subject to shareholder and regulatory approvals
- Redx management team to lead combined company; headquarters in Alderley Park, UK
Financial Impact
Skye shareholders diluted to ~5.38% ownership; combined company receives ~$125M in new financing; CVR provides contingent upside from nimacimab monetization
Risk Factors
- Transaction may fail to close due to shareholder or regulatory approval
- Extreme dilution for existing Skye shareholders
- CVR may yield minimal or no proceeds if nimacimab is not monetized
- RXC008 Phase 2 clinical risk; fibrostenotic Crohn's is a high-unmet-need but unproven target
- Integration risk and execution risk under new management
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345392 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | DEFA14A | $0.2809 $1.77 | ▲ +528.34% | ▲ +528.34% | $1.68 (+498.08%) |
Aug 14, 2026 7w ago | 8-K | $0.5015 $1.99 | ▲ +296.81% | ▲ +298.80% | $1.68 (+235.00%) |
Aug 14, 2026 7w ago | Press Release | $0.5015 $1.99 | ▼ −296.81% | ▼ −298.80% | $1.68 (−235.00%) |
May 15, 2026 20w ago | 8-K | $0.7780 $0.7184 | ▲ +7.66% | ▲ +9.24% | $1.68 (−115.94%) |
May 12, 2026 20w ago | Press Release | $0.8140 $0.7800 | ▲ +4.18% | ▲ +2.45% | $1.68 (−106.39%) |
Apr 29, 2026 22w ago | 3 | $0.8940 $0.8500 | ▼ −4.92% | ▼ −10.97% | $1.68 (+87.92%) |
Apr 16, 2026 24w ago | DEFA14A | $0.7500 $0.8200 | ▲ +9.33% | ▲ +3.52% | $1.68 (+124.00%) |
Apr 2, 2026 26w ago | Press Release | $0.6980 $0.8790 | ▲ +25.93% | ▲ +16.05% | $1.68 (+140.69%) |
Mar 10, 2026 29w ago | Press Release | $0.7210 $0.7260 | ▲ +0.69% | ▲ +0.17% | $1.68 (+133.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access